Our Services
Medical Information
Helpful Resources
Published on: 9/22/2026
Travelers with narcolepsy generally need their medication in the original pharmacy-labeled container, a copy of the prescription, and a signed letter from the prescribing clinician confirming the diagnosis, the medication names and dosages, and why the treatment is medically necessary, since stimulants and sodium oxybate are controlled substances in most countries. Some destinations also require advance import permits, embassy approval, quantity limits such as a 30-day supply, or ban certain narcolepsy drugs entirely, and liquid medications may need to be declared at security screening. There are several country-specific rules and timing steps that can derail a trip if missed, so review the complete details below before you book or pack.
If excessive daytime sleepiness, sleep attacks, or sudden muscle weakness are part of your daily life, understanding what is driving those symptoms is just as important as having the right paperwork. Take a free, instant, online symptom check to see which conditions may match your pattern and get clear guidance on the next steps to discuss with a clinician.
Last reviewed for medical accuracy: 09/22/2026
Traveling with narcolepsy medication can feel daunting, but the right paperwork helps ensure a smooth journey. Whether you’re flying across the country or crossing international borders, gathering essential documentation minimizes delays, prevents confiscations and keeps your treatment on track.
Narcolepsy medications—often including stimulants (methylphenidate, amphetamine salts), wake-promoting agents (modafinil, armodafinil), or newer treatments—are frequently classified as controlled substances. Governments and airlines enforce strict rules to prevent misuse. Proper paperwork:
When flying within the United States, the Transportation Security Administration (TSA) and the Drug Enforcement Administration (DEA) set guidelines for prescription medications:
Original Prescription Container
Copy of Your Prescription
Doctor’s Note (Optional but Helpful)
Quantity Documentation
TSA 605 Form (when needed)
Each country has its own rules regarding controlled and prescription medications. Start preparing at least 6–8 weeks before departure:
Research Destination Regulations
Doctor’s Letter of Medical Necessity
Translation (if Required)
International Narcotics Control Board (INCB) Certificate
Local Import Permits
Keep Everything Accessible
Notify Security Officers
At TSA checkpoints or foreign customs, inform officers that you carry prescription meds before screening begins.
Separate Medications
Keep pills in a clear, sealable bag or pouch for quick inspection.
Plan Extra Time
Arrive at the airport at least 90 minutes before domestic flights, 2–3 hours for international.
Check Airline Policies
Some carriers have additional forms or rules for controlled substances.
Q: Can I ship my medication to my destination?
A: Shipping controlled substances across borders is generally illegal. Always travel with meds in your possession.
Q: Am I allowed to travel with syringes or injectable meds?
A: Yes, if properly documented. Carry a doctor’s note explaining medical necessity and instructions.
Q: What if I lose my medication or documentation?
A:
Planning travel takes effort, and narcolepsy symptoms can fluctuate. Before you go, track your sleepiness, cataplexy episodes or any side effects you’re experiencing. You might consider a free, online symptom check, using the doctor approved Ubie Symptom Checker to:
Any time you face:
Reach out to your healthcare provider. If you experience life-threatening or serious issues—chest pain, severe allergic reactions, suicidal thoughts—seek emergency care immediately.
Safe travels start with preparation. By gathering the right documents and staying in touch with your medical team, you can keep your narcolepsy treatment on track and focus on enjoying your journey. If you have questions about paperwork or need urgent medical advice, speak to a doctor.
(References)
* Masullo A, Feola A, Marino V, Iadevaia C, Trabucco Aurilio M, Marsella LT. Sleep disorders and driving licence: the current Italian legislation and medico-legal issues. Clin Ter. 2014;165(5):e368-72. doi: 10.7417/CT.2014.1766. PMID: 25366956.
* Vandi S, Pizza F, Antelmi E, Neccia G, Iloti M, Mazzoni A, Avoni P, Plazzi G. A standardized test to document cataplexy. Sleep Med. 2019 Jan;53:197-204. doi: 10.1016/j.sleep.2017.08.021. Epub 2017 Oct 9. PMID: 29276000.
* Bartolini I, Pizza F, Di Luzio A, Neccia G, Antelmi E, Vandi S, Plazzi G. Automatic detection of cataplexy. Sleep Med. 2018 Dec;52:7-13. doi: 10.1016/j.sleep.2018.07.018. Epub 2018 Aug 10. PMID: 30195199.
* Carlier J, Giorgetti R, Varì MR, Pirani F, Ricci G, Busardò FP. Use of cognitive enhancers: methylphenidate and analogs. Eur Rev Med Pharmacol Sci. 2019 Jan;23(1):3-15. doi: 10.26355/eurrev_201901_16741. PMID: 30657540.
* Advice for travelers. Med Lett Drugs Ther. 2019 Oct 7;61(1582):153-160. PMID: 31599872.
* Grigg-Damberger M, Andrews N, Wang L, Bena J, Foldvary-Schaefer N. Subjective and objective hypersomnia highly prevalent in adults with epilepsy. Epilepsy Behav. 2020 May;106:107023. doi: 10.1016/j.yebeh.2020.107023. Epub 2020 Mar 23. PMID: 32213453.
* Varughese RT, Kothare SV, Franceschi AM. 18F-FDG Brain PET Findings in Narcolepsy Type 2. Clin Nucl Med. 2022 Aug 1;47(8):e559-e561. doi: 10.1097/RLU.0000000000004264. Epub 2022 May 19. PMID: 35797634.
* Roy A, Ito D, Morris S, Candler S, Profant J, Bae C. Individualized Treatment Patterns for Patients with Narcolepsy Treated with Oxybate: A Clinical Practice Perspective. Nat Sci Sleep. 2023;15:767-778. doi: 10.2147/NSS.S411727. Epub 2023 Sep 29. PMID: 37799734; PMCID: PMC10547908.
* Tang SH, Min J, Zhang X, Uwah E, Griffis HM, Cielo CM, Fiks AG, Mindell JA, Tapia IE, Williamson AA. Incidence of pediatric narcolepsy diagnosis and management: evidence from claims data. J Clin Sleep Med. 2024 Jul 1;20(7):1141-1151. doi: 10.5664/jcsm.11104. PMID: 38450539; PMCID: PMC11217630.
* Sarpatwari A, Lee SB, Zakoul H, Tekle W, Freedman A, Belitkar S, Toyserkani GA, LaCivita C, Zhou EH, Oswell KH, Dal Pan GJ, Kesselheim AS. Patient Perceptions of and Experiences with Risk Evaluation and Mitigation Strategies. Clin Pharmacol Ther. 2026 Jan;119(1):267-275. doi: 10.1002/cpt.70091. Epub 2025 Oct 11. PMID: 41074573.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.